{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:06Z","timestamp":1789135926756,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tacrolimus is a critical immunosuppressant that requires therapeutic drug monitoring because of its narrow therapeutic index and erratic pharmacokinetics. Although liquid chromatography\u2013tandem mass spectrometry (LC-MS\/MS) has been deemed the \u201cgold standard\u201d for tacrolimus quantitation, immunoassays are widely used in practice because of their suitability for automation and their accessibility. However, interassay variability poses risks of dosing errors and therapeutic mismanagement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors compared Siemens Atellica CH and Abbott ARCHITECT i2000 tacrolimus immunoassays with LC-MS\/MS as the reference method. Forty whole blood samples from transplant recipients were used. The Clinical and Laboratory Standards Institute guidelines were followed for the method comparison, linearity, and precision studies. Deming regression and Bland\u2013Altman plots were used to evaluate agreement and bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Both immunoassays exhibited good precision (coefficient of variation &lt;15%) and linearity over the range established by the manufacturer. The results for both platforms correlated well with the LC-MS\/MS results (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      &gt; 0.97). The Siemens Atellica and Abbott ARCHITECT methods showed negative biases of \u221213.8% and \u22126.6%, respectively, compared with LC-MS\/MS. A mean difference of \u221214.3% was observed between the 2 immunoassays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although both immunoassays met the performance standards, systematic negative bias, particularly with the Siemens Atellica method, may have affected tacrolimus dosing in the transplant recipients. Method-specific variability underscores the need for a stable monitoring platform or to re-establish the baseline during a method changeover. LC-MS\/MS remains an essential method for verifying patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001509","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:00:10Z","timestamp":1784120410000},"page":"680-685","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Evaluation of Siemens Atellica and Abbott ARCHITECT Tacrolimus Immunoassays Against LC-MS\/MS: A Short Communication"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-5420","authenticated-orcid":false,"given":"Rebecca J.","family":"Wilson","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, Ohio"},{"name":"Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gowans","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, Ohio"},{"name":"Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Fatica","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"suppl S1","key":"R1-20260911","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ajt.15672","article-title":"OPTN\/SRTR 2018 annual data report: kidney","volume":"20","author":"Hart","year":"2020","journal-title":"Am J Transpl."},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"e70047","DOI":"10.1111\/apha.70047","article-title":"Calcineurin inhibitor associated nephrotoxicity in kidney transplantation-a transplant nephrologist's perspective","volume":"241","author":"Hansen","year":"2025","journal-title":"Acta Physiol (Oxf)."},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bcp.13047","article-title":"Therapeutic drug monitoring in the era of precision medicine: opportunities","volume":"82","author":"Cremers","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","article-title":"Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients","volume":"13","author":"Andrews","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/labmed\/lmx056","article-title":"Tacrolimus: a review of laboratory detection methods and indications for use","volume":"48","author":"Kalt","year":"2017","journal-title":"Lab Med."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2015.12.027","article-title":"Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry","volume":"454","author":"McShane","year":"2016","journal-title":"Clin Chim Acta."},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/dta.2290","article-title":"Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs","volume":"10","author":"Zhang","year":"2018","journal-title":"Drug Test Anal."},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40780-023-00318-6","article-title":"Validation of an automated sample preparation module directly connected to LC-MS\/MS (CLAM-LC-MS\/MS system) and comparison with conventional immunoassays for quantitation of tacrolimus and cyclosporin A in a clinical setting","volume":"10","author":"Shimada","year":"2024","journal-title":"J Pharm Health Care Sci."},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"e22587","DOI":"10.1002\/jcla.22587","article-title":"Comparison of whole-blood tacrolimus concentrations measured by different immunoassay systems","volume":"32","author":"Kaneko","year":"2018","journal-title":"J Clin Lab Anal."},{"key":"R12-20260911","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvad097.626","article-title":"B-306 performance evaluation of an automated assay for measurement of tacrolimus* on the ADVIA Centaur XP system","volume":"69","author":"Chuang RS","year":"2023","journal-title":"Clin Chem."},{"issue":"suppl 1","key":"R13-20260911","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/ajcp\/aqae129.397","article-title":"Comparison of five tacrolimus measurement methods underscore the need for a standardized method to improve clinical outcomes","volume":"162","author":"Bandar","year":"2024","journal-title":"Am J Clin Pathol."},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3343\/alm.2018.38.2.85","article-title":"Multi-center performance evaluations of tacrolimus and cyclosporine electrochemiluminescence immunoassays in the Asia-Pacific region","volume":"38","author":"Qin","year":"2018","journal-title":"Ann Lab Med."},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1373\/clinchem.2011.172080","article-title":"The need for standardization of tacrolimus assays","volume":"57","author":"Levine","year":"2011","journal-title":"Clin Chem."},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"1716789","DOI":"10.3389\/frtra.2025.1716789","article-title":"Comparative evaluation of five tacrolimus assays in transplant recipients: implications for optimizing therapeutic drug monitoring","volume":"4","author":"SahBandar","year":"2025","journal-title":"Front Transpl."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/FTD.0000000000000205","article-title":"impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs","volume":"37","author":"Christians","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"e22357","DOI":"10.1002\/jcla.22357","article-title":"Performance of the Dimension TAC assay and comparison of multiple platforms for the measurement of tacrolimus","volume":"32","author":"Cho","year":"2018","journal-title":"J Clin Lab Anal."},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/FTD.0000000000000331","article-title":"Evaluation of the new Siemens Tacrolimus Assay on the dimension EXL Integrated Chemistry System Analyzer: comparison with an ultra-performance liquid chromatography-tandem mass spectrometry method","volume":"38","author":"Bargnoux","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/FTD.0000000000000696","article-title":"Comparison of 4 commercial immunoassays used in measuring the concentration of tacrolimus in blood and their cross-reactivity to its metabolites","volume":"42","author":"Shigematsu","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jcpt.13075","article-title":"Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review","volume":"45","author":"He","year":"2020","journal-title":"J Clin Pharm Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:41Z","timestamp":1789135241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001509","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2025-10-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}